Opening question: When a research-peptide listing flashes a SignalP screenshot, a “signal peptide predicted” badge, or a claim that a sequence is “cleavage-site verified,” how do you tell a signal-peptide prediction server from proof that a vial is cleared for people?
Short answer: open the SignalP 6.0 server page at DTU Health Tech and the open SignalP 6.0 PubMed record for the Nature Biotechnology methods paper (DOI 10.1038/s41587-021-01156-3). SignalP 6.0 predicts the presence of signal peptides and the location of their cleavage sites in proteins from Archaea, Gram-positive and Gram-negative Bacteria, and Eukarya. In bacteria and archaea it can discriminate among five signal-peptide types (Sec/SPI, Sec/SPII, Tat/SPI, Tat/SPII, and Sec/SPIII) and predicts n-, h-, and c-regions where relevant. That is protein-sorting research literacy—not a medicines review of a catalog SKU.
A practical SignalP checklist when ads lean on prediction screenshots:
- What the server actually claims: The DTU page describes SignalP 6.0 as a prediction service for signal peptides and cleavage-site locations across domains of life, built on a transformer protein language model with a conditional random field for structured prediction. A predicted cleavage site is a computational annotation, not pharmacy clearance for a research peptide.
- Five types ≠ five product approvals: Discriminating Sec versus Tat pathways and SPI/SPII/SPIII peptidases helps biologists interpret how proteins are exported and processed. It does not authorize human or veterinary use of a nearby research vial.
- Region maps stay structural hypotheses: Predicted n-, h-, and c-regions help readers visualize signal-peptide organization. Region plots in an ad do not create clinical evidence for a research-only listing.
- Keep prediction tools separate from curated PTM databases: SignalP predicts where a signal peptide may be removed. That is different from browsing curated phosphorylation maps or deposited proteomics datasets. Ads sometimes blur “predicted cleavage” with “experimentally confirmed product identity”—those are different claims.
- What to open next: If an ad implies a research peptide is “SignalP-verified,” open the DTU service page and the methods paper record and ask whether the claim is about signal-peptide literacy—or about decorating a research-only SKU with a bioinformatics badge.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use SignalP to understand how researchers predict secretory signal peptides and cleavage sites, then ask whether the ad is teaching that distinction or implying a research peptide is medically meaningful because a prediction plot looks official. That habit changes what you notice in catalogs—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the SignalP 6.0 DTU service page and PubMed 34980915 (fetched 2026-09-30 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. SignalP 6.0 — DTU Health Tech Bioinformatic Services
2. PubMed — SignalP 6.0 methods paper record (PMID 34980915)
3. Apollo Peptides (company facts only)
Related reading
How to read PeptideCutter when peptide ads flash cleavage-prediction screenshots
How to read PhosphoSitePlus when peptide ads flash phospho maps